Insomnia as clinical onset symptom in Juvenile Huntington’s Disease: Evaluation of a Family
Objective: The aim of this study to emphasize that three juvenile form of HD cases who have insomnia as clinical onset symptoms. Background: Huntington’s Disease…A global survey on speech language therapists’ awareness to Huntington’s disease
Objective: To investigate the awareness and knowledge of speech and language therapists (SLTs) on Huntington’s disease (HD) worldwide, and to explore the clinical practice and…Novel exploratory outcome assessments in GENERATION HD1
Objective: To improve collection of outcomes meaningful to patients with Huntington’s disease (HD) and their families, through the development of novel assessments of daily functional…A Multiple Ascending-Dose Study of LY3154207, A Dopamine D1 Receptor Positive Allosteric Modulator (D1PAM)
Objective: Evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple oral LY3154207 (LY) doses in healthy subjects (HS) and persons with Parkinson’s disease (PWPD). Background:…Analysis of Levodopa Content in Commercial Formulations of Mucuna pruriens Seeds Used in Integrative Treatment of Parkinson’s Disease
Objective: Objective: Formulations of Mucuna pruriens (MP) seed products are readily available through the internet and health food stores, and are used by some Parkinson's…Effects of zonisamide on parkinsonism in patients with dementia with Lewy bodies by severity of cognitive dysfunction and BPSD: subgroup analysis of pooled data from two trials
Objective: To characterize the efficacy and safety of zonisamide (ZNS) in patients with dementia with Lewy bodies (DLB) with parkinsonism, we performed subgroup analysis by…A study for expanding application sites of rotigotine transdermal patch
Objective: We examined to see whether to expand application sites of RTP other than the approved application sites. Background: Rotigotine transdermal patch (RTP) is a dopamine…Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with or without baseline presence of dyskinesia (BPDys). Background: OPC, a…Biphasic Dyskinesias in Parkinson’s disease Patients treated with Levodopa/Carbidopa Intestinal Gel: Insights from a Multicenter Retrospective Analysis
Objective: We aimed to characterize Parkinson's disease (PD) patients who developed the onset of new troublesome dyskinesias after Levodopa-Carbidopa Intestinal Gel (LCIG) initiation. We were…Opicapone improves motor and non-motor wearing off symptoms in Parkinson’s disease: an observational real-world study
Objective: To assess the impact of opicapone - a third generation COMT Inhibitor - on motor and non-motor wearing off symptoms in patients suffering from…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 217
- Next Page »